日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CD8 PET imaging with [(89)Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study

CD8 PET 显像联合 [(89)Zr]Zr-berdoxam-crefmirlimab 用于实体瘤患者:II 期 iCorrelate 研究

Postow, Michael A; Zang, Peter D; Pal, Sumanta K; Mauguen, Audrey; Farwell, Michael; Gordon, Michael; Hays, David; Wong, Jeffrey Y C; Chen, Delphine; Ulaner, Gary A; Esposito, Giuseppe; McConathy, Jonathan; Graham, Michael M; Shields, Anthony F; Van den Abbeele, Annick D; Butler, Marcus O; Thomas, Jacob S; Twardowski, Przemyslaw; Narang, Jayant; Singh, Aman P; Dey, Agnish; Maresca, Kevin P; Keliher, Edmund; Liu, Feng; Potdevin, Guillaume; Schmidt, Guenter; Le, William; Wilson, Ian; Mascioni, Alessandro; Jia, Fang; Korn, Ronald; Ferris, Michael R; Schmiedehausen, Kristin; Pandit-Taskar, Neeta; Margolin, Kim A

Immune Modulation During Treatment with Enzalutamide Alone or with Radium-223 in Patients with Castration Resistant Prostate Cancer.

去势抵抗性前列腺癌患者接受恩扎卢胺单药治疗或联合镭-223治疗期间的免疫调节

Zang Peter D, Da Silva Diane M, Liu Zhang-Xu, Kandukuri Shivani, Tsao-Wei Denice, D'Souza Anishka, Kast W Martin, Pal Sumanta K, Kefauver Cheryl, Juanqueira Maribel, Yang Lixin, Quinn David I, Dorff Tanya B

Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma

抗体-药物偶联物联合疗法治疗晚期尿路上皮癌的疗效和安全性

Jaime-Casas, Salvador; Barragan-Carrillo, Regina; Zugman, Miguel; Shah, Koral; Ebrahimi, Hedyeh; Mercier, Benjamin; Castro, Daniela V; Zang, Peter D; LeVee, Alexis; Yip, Wesley; Li, Xiaochen; Dizman, Nazli; Salgia, Nicholas J; Zengin, Zeynep; Meza, Luis; Hsu, JoAnn; Nguyen, Charles B; Chehrazi-Raffle, Alexander; Pal, Sumanta K; Tripathi, Abhishek

Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition

转移性去势抵抗性前列腺癌的肿瘤突变负荷与免疫检查点抑制剂的反应

Zang, Peter D; Chawla, Neal S; Barragan-Carrillo, Regina; Chehrazi-Raffle, Alex; Tripathi, Abhishek; Pal, Sumanta K; Dorff, Tanya B